Form 4: Aktis Oncology Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Akos Czibere, Chief Medical Officer of Aktis Oncology, Inc., sold 12,500 shares of common stock on September 23, 2026.

Summary

  • Option exercise/conversion: acquired 12,500 Common Stock at $4.95 ($61,875) on September 23, 2026; holds 12,500 after (Direct).
  • Open-market sale: disposed of 5,099 Common Stock at $20.19 ($102,973) on September 23, 2026; holds 7,401 after (Direct).
  • Open-market sale: disposed of 7,401 Common Stock at $21.03 ($155,648) on September 23, 2026 (Direct).
  • Option exercise/conversion: disposed of 12,500 Stock Option (Right to Buy) on September 23, 2026; holds 208,718 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $258,621 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Akos Czibere — Officer (Chief Medical Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-23Option exercise/conversionCommon Stock12,500$5$61.9K12,500
2026-09-23Open-market saleCommon Stock5,099$20$103.0K7,401
2026-09-23Open-market saleCommon Stock7,401$21$155.6K0
2026-09-23Option exercise/conversionStock Option (Right to Buy)12,500——208,718

Key Dates

DateDescription
2026-09-23Option exercise/conversion (12,500 shares)
2026-09-23Open-market sale (5,099 shares)
2026-09-23Open-market sale (7,401 shares)
2026-09-23Option exercise/conversion (12,500 shares)

Keywords

insider transaction, Form 4, AKTS, Aktis Oncology, Inc., bearish, Akos Czibere

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.